Influence_NN
of_IN
estradiol_NN
and_CC
tamoxifen_NN
on_IN
susceptibility_NN
of_IN
human_JJ
breast_NN
cancer_NN
cell_NN
lines_NNS
to_TO
lysis_NN
by_IN
lymphokine-activated_JJ
killer_NN
cells_NNS
._.

The_DT
design_NN
of_IN
combination_NN
hormonal_JJ
and_CC
immunotherapeutic_JJ
protocols_NNS
for_IN
breast_NN
cancer_NN
patients_NNS
may_MD
be_VB
facilitated_VBN
by_IN
analysis_NN
of_IN
preclinical_JJ
in_FW
vitro_FW
model_NN
systems_NNS
._.

Estrogen_NN
receptor_NN
positive_JJ
-LRB-_-LRB-
ER_NN
+_NN
:_:
MCF-7_NN
-RRB-_-RRB-
and_CC
negative_JJ
-LRB-_-LRB-
ER_NN
-_:
:_:
MDA-MB-231_NN
-RRB-_-RRB-
human_JJ
breast_NN
cancer_NN
cell_NN
lines_NNS
were_VBD
utilized_VBN
to_TO
evaluate_VB
the_DT
effects_NNS
of_IN
tamoxifen_NN
-LRB-_-LRB-
TAM_NN
-RRB-_-RRB-
and_CC
estradiol_NN
-LRB-_-LRB-
E2_NN
-RRB-_-RRB-
on_IN
modulation_NN
of_IN
breast_NN
cancer_NN
target_NN
susceptibility_NN
to_TO
lysis_NN
by_IN
lymphokine-activated_JJ
killer_NN
-LRB-_-LRB-
LAK_NN
-RRB-_-RRB-
cells_NNS
._.

E2-stimulated_JJ
ER_NN
+_CC
cells_NNS
were_VBD
more_RBR
susceptible_JJ
to_TO
lysis_NN
by_IN
LAK_NN
cells_NNS
than_IN
corresponding_VBG
TAM-treated_JJ
or_CC
control_NN
cells_NNS
,_,
while_IN
treatment_NN
of_IN
ER_NN
-_:
cells_NNS
with_IN
either_CC
E2_NN
or_CC
TAM_NN
alone_RB
did_VBD
not_RB
alter_VB
from_IN
control_JJ
their_PRP$
susceptibility_NN
to_TO
this_DT
immune-mediated_JJ
lysis_NN
._.

All_DT
ER_NN
+_CC
and_CC
ER_NN
-_:
cells_NNS
tested_VBN
remained_VBD
sensitive_JJ
after_IN
treatment_NN
with_IN
TAM_NN
to_TO
lysis_NN
by_IN
LAK_NN
cells_NNS
._.

In_IN
addition_NN
,_,
an_DT
adenocarcinoma_NN
reactive_JJ
human-mouse_NN
chimeric_JJ
monoclonal_JJ
antibody_NN
-LRB-_-LRB-
ING-1_NN
-RRB-_-RRB-
was_VBD
able_JJ
to_TO
significantly_RB
boost_VB
in_FW
vivo_FW
generated_VBN
LAK_NN
cell-mediated_JJ
lysis_NN
of_IN
control_NN
,_,
E2-treated_JJ
,_,
and_CC
TAM-treated_JJ
ER_NN
+_CC
and_CC
ER_NN
-_:
cells_NNS
._.

These_DT
in_FW
vitro_FW
results_NNS
provide_VBP
a_DT
preclinical_JJ
rationale_NN
for_IN
in_FW
vivo_FW
testing_NN
of_IN
TAM_NN
,_,
interleukin-2_NN
-LRB-_-LRB-
IL-2_NN
-RRB-_-RRB-
,_,
and_CC
breast_NN
cancer_NN
reactive_JJ
antibody-dependent_JJ
cellular_JJ
cytotoxicity_NN
facilitating_VBG
antibody_NN
in_IN
patients_NNS
with_IN
refractory_JJ
or_CC
high_JJ
risk_NN
breast_NN
cancer_NN
._.

